Sigma-Aldrich and CPC Scientific Signs Distribution Agreement for Custom Peptide Libraries
News Jan 30, 2009
Sigma-Aldrich has announced that it has signed a distribution agreement with CPC Scientific. Under the terms of the agreement, CPC Scientific will offer Sigma-Aldrich's PEPscreen® custom peptide libraries to life science researchers and pharmaceutical companies in North America.
Sigma- Aldrich has developed a proprietary synthesis platform that enables the high throughput production of milligram quantities of peptides, which are ideal for producing custom peptide libraries applicable to peptide based drug discovery.
"In Sigma-Aldrich, we've found an experienced partner for the production of custom peptide libraries," said Dr. Shawn Lee, President & CEO of CPC Scientific. "The addition of PEPscreen custom peptide libraries to our portfolio benefits our customers by addressing the early research phase of peptide screening in the drug discovery workflow."
Sigma-Aldrich's peptide synthesis process significantly reduces the time required for peptide library development, reducing costs in the drug development process. The company's customized peptide libraries are utilized by the biotechnology industry to target active areas of small biological molecules with potential therapeutic properties.
"Our PEPscreen technology enables small scale, early stage drug candidate screenings," said Stacey Hoge, Senior Product Manager at Sigma-Aldrich. "CPC's close association with the pharmaceutical and biotechnology industry provides great opportunities for Sigma-Aldrich to further engage drug discovery researchers."
Concept Life Sciences appoints New Group Programme Manager and US Head of SalesNews
Key leadership appointments support integration of the Group and expansion in the US market.READ MORE
Blood-vessel-on-a-chip Provides Insight into Novel Anti-Inflammatory Drug CandidateNews
Researchers have discovered that synthetic APC-mimicking small molecules called “parmodulins” provide anti-inflammatory and anti-thrombotic protection to endothelial cells on par with APC’s without interfering with normal blood clotting and coagulation, making them attractive new drug candidates.READ MORE